In Plain English:
Nonapeptide-1, sold under trade names Melitane and Melanostatine-5 (Lucas Meyer Cosmetics / IFF), is a synthetic nine-amino-acid peptide derived from the alpha-melanocyte-stimulating hormone (alpha-MSH) sequence. It was first characterised in 1994 by Jayawickreme et al. at Yale University as the most potent member of a 31,360-compound peptide library screened for MC1R-blocking activity. The sequence Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2 incorporates two D-form amino acids at positions 3 and 5 — a structural feature that locks the peptide into a conformation that competes with alpha-MSH for binding to the melanocortin-1 receptor (MC1R) on melanocyte surfaces. By occupying MC1R without activating it (competitive antagonism), Nonapeptide-1 interrupts the cAMP/PKA/CREB/MITF cascade that drives tyrosinase expression and melanin synthesis — acting upstream of every existing brightening agent (hydroquinone, arbutin, kojic acid, niacinamide), which all work at the enzyme level or further downstream. Published manufacturer data reports 33% melanin reduction vs. untreated controls. A 2025 RCT (Shen et al., n=62) used a formulation containing 3% Nonapeptide-1 alongside arbutin, Cordyceps extract, and glabridin and showed 35.3% MASI score reduction and 25% melanin index drop over 12 weeks — equivalent to the hydroquinone control arm. Expert opinion is divided: cosmetic chemist Hannah Sivak (PhD) notes the 1994 Jayawickreme study used frog melanocytes, that human in vivo evidence remains sparse, and that co-formulated actives likely confound efficacy claims. INCI-listed as a cosmetic ingredient in the US, EU, and UK; not approved or classified as a pharmaceutical anywhere. The Melanostatine-5 BG trade product is formulated in water/butylene glycol/dextran at 4–8% inclusion in the final blend.
Research Maturity
Early Human (~25 PubMed results; 1 seminal in vitro study (1994); only RCT (2025) is multi-ingredient+ Studies)
Focus
Cosmetic Dermatology
Skin Pigmentation
Origin
Sequence Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2 first isolated by Jayawickreme CK, Quillan JM, Graminski GF, Lerner MR at Yale University School of Medicine, published November 1994 (J Biol Chem 269(47):29846-54, PMID 7961978). The peptide was identified from a combinatorial library of 31,360 candidates derived from the alpha-MSH[5-13] subsequence. Commercialised by Lucas Meyer Cosmetics (now IFF) as Melanostatine-5 (Melanostatine-5 BG and Melanostatine-5 PS variants). Also referred to as Melitane in research peptide trade contexts. INCI registered as Nonapeptide-1; CAS 158563-45-2; PubChem CID 10418849.
Mechanism
Competitive antagonist at the melanocortin-1 receptor (MC1R; Ki = 40 nM; selective over MC3R, MC4R, MC5R by several orders of magnitude). Inhibits intracellular cAMP accumulation induced by alpha-MSH (IC50 = 2.5 nM) and melanosome dispersion (IC50 = 11 nM) in melanocyte cell culture (Jayawickreme 1994). Downstream effects: suppression of cAMP elevation blocks protein kinase A (PKA) activation, preventing CREB phosphorylation, which reduces transcription of MITF (microphthalmia-associated transcription factor) — the master regulator of melanogenesis. MITF downregulation reduces expression of tyrosinase (rate-limiting melanin enzyme), TRP1, and TRP2, collectively cutting melanin output. The two D-amino acids (D-Phe³, D-Trp⁵) are essential for antagonistic (vs. agonistic) activity and confer resistance to proteolytic degradation, improving topical stability vs. all-L-amino acid peptides. Peptide Design review (Putri et al., 2025, Drug Des Devel Ther) notes that cyclization and polarity optimisation of MC1R-targeting peptides (RFWG-NH2, RLWG-NH2 analogues) further potentiate MC1R blockade — placing Nonapeptide-1 in a broader class of competitive MC1R antagonist peptides.
Outcome
Jayawickreme 1994 (in vitro, frog/Xenopus melanocytes): IC50 2.5 nM (cAMP inhibition), 11 nM (melanosome dispersion); Ki 40 nM at MC1R. Lucas Meyer Cosmetics manufacturer data (method not independently verified): 33% melanin production reduction vs. untreated melanocytes; 28-day clinical claim for equalization of skin tone with Melanostatine-5 at 4–8% inclusion. Shen S et al. 2025 (J Cosmet Dermatol, PMID 40590148, PMCID PMC12210096): 12-week RCT n=62 women with melasma; Group B received oral tranexamic acid + topical Cordyceps essence (nonapeptide-1 3%, arbutin 0.5%, glabridin 3%, Cordyceps extract 0.2%); MASI score reduced 35.31% (11.13 → 7.20, p<0.001); melanin index reduced 25.02% (174.63 → 130.93, p<0.001); adverse reactions: 1 patient (3.3%) pruritus only. No significant difference vs. hydroquinone-containing control arm (p=0.620 for MASI). In vitro biomarker study (Biotech Peptides, 2024 summary): diminished expression of tyrosinase, TRP1, TRP2, and MITF in UVA-irradiated melanocytes at clinically relevant concentrations. Pilot RCT reported in PeptideInsight (double-blind, 8-month): observable MASI and melanin index improvement vs. control; full data not independently verifiable from open-access sources.
